RxDoctor Payments Data

Ranley Desir, MD

Cardiology · Aventura, FLNPI 1629071576

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.8% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Medtronic at 36.0% of the total.

$2,637in general payments, 2019–2025

Across 53 payments — averaging $49.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$949
  • Abbott$536
  • Pfizer$283
  • E.r. Squibb & Sons, L.L.C.$260
  • Heartflow, Inc.$146
  • Boston Scientific$116
  • plus $346 from 10 others

What the payments were for

  • Food & beverage$2,631100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,637 in reported general payments places this provider in the 75th percentile of 45 cardiology providers in Florida.

See all cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$782,483
Medicare patients
792
Services billed
5,300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis16$407,429
EliquisApixaban306$295,557
EntrestoSacubitril/Valsartan93$96,704
CamzyosMavacamten14$93,665
XareltoRivaroxaban51$63,694
Repatha SureclickEvolocumab60$55,956
Praluent PenAlirocumab21$21,114
Repatha PushtronexEvolocumab13$11,291
FarxigaDapagliflozin Propanediol20$8,539
BystolicNebivolol Hcl16$6,817
Metoprolol Succinate362$5,620
Pitavastatin Calcium12$4,512
SynthroidLevothyroxine Sodium43$4,432
Ranolazine ErRanolazine52$4,241
Atorvastatin Calcium355$4,164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$283$702,986322 claims
NovartisEntresto$47$96,70493 claims
E.r. Squibb & Sons, L.L.C.Camzyos$260$93,66514 claims
Johnson & JohnsonXarelto$90$63,69451 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 45 cardiology providers in Florida.

Other cardiology in Aventura

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →